{"id":"https://openalex.org/W2979748813","doi":"https://doi.org/10.1182/blood.v128.22.524.524","title":"Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia","display_name":"Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia","publication_year":2016,"publication_date":"2016-12-02","ids":{"openalex":"https://openalex.org/W2979748813","doi":"https://doi.org/10.1182/blood.v128.22.524.524","mag":"2979748813"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v128.22.524.524","doi":"https://doi.org/10.1182/blood.v128.22.524.524","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.524.524","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074563113","display_name":"Sara J. Buhrlage","orcid":"https://orcid.org/0000-0003-4562-1823","observed_orcids":["https://orcid.org/0000-0003-4562-1823"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sara Buhrlage","raw_affiliation_strings":["Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055853326","display_name":"Ellen Weisberg","orcid":"https://orcid.org/0000-0002-5679-9531","observed_orcids":["https://orcid.org/0000-0002-5679-9531"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ellen Weisberg","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047511531","display_name":"Nathan J. Schauer","orcid":"https://orcid.org/0000-0002-3004-4923","observed_orcids":["https://orcid.org/0000-0002-3004-4923"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nathan Schauer","raw_affiliation_strings":["Harvard University, Cambridge,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard University, Cambridge,","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074112736","display_name":"Jing Chun Yang","orcid":"https://orcid.org/0000-0001-6441-709X","observed_orcids":["https://orcid.org/0000-0001-6441-709X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jing Yang","raw_affiliation_strings":["Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045615826","display_name":"Ilaria Lamberto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ilaria Lamberto","raw_affiliation_strings":["Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033992816","display_name":"Laura M. Doherty","orcid":"https://orcid.org/0000-0002-8171-5109","observed_orcids":["https://orcid.org/0000-0002-8171-5109"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Laura Doherty","raw_affiliation_strings":["Harvard University, Cambridge,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard University, Cambridge,","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047404508","display_name":"Atsushi Nonami","orcid":"https://orcid.org/0009-0001-8153-7082","observed_orcids":["https://orcid.org/0009-0001-8153-7082"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Atsushi Nonami","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038598397","display_name":"Amanda L. Christie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amanda L. Christie","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026688095","display_name":"David M. Weinstock","orcid":"https://orcid.org/0000-0002-8724-3907","observed_orcids":["https://orcid.org/0000-0002-8724-3907"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Weinstock","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071023119","display_name":"Richard Maury Stone","orcid":"https://orcid.org/0000-0002-7526-2633","observed_orcids":["https://orcid.org/0000-0002-7526-2633"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard M. Stone","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022352605","display_name":"Nathanael S. Gray","orcid":"https://orcid.org/0000-0001-5354-7403","observed_orcids":["https://orcid.org/0000-0001-5354-7403"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nathanael Gray","raw_affiliation_strings":["Cancer Biology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Biology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039503690","display_name":"James D. Griffin","orcid":"https://orcid.org/0000-0003-1823-7930","observed_orcids":["https://orcid.org/0000-0003-1823-7930"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James D Griffin","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5022352605","https://openalex.org/A5033992816","https://openalex.org/A5045615826","https://openalex.org/A5047511531","https://openalex.org/A5055853326","https://openalex.org/A5074112736","https://openalex.org/A5074563113"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.3168,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.72937412,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"128","issue":"22","first_page":"524","last_page":"524"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9653000235557556,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9653000235557556,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.013899999670684338,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.011599999852478504,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/usp10","display_name":"USP10","score":0.9340000152587891},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.8399999737739563},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9739999771118164},{"id":"https://openalex.org/keywords/deubiquitinase","display_name":"deubiquitinase","score":0.8240000009536743},{"id":"https://openalex.org/keywords/protein-degradation","display_name":"protein degradation","score":0.5619999766349792},{"id":"https://openalex.org/keywords/ubiquitin-mediated-degradation","display_name":"ubiquitin-mediated proteolysis","score":0.7829999923706055},{"id":"https://openalex.org/keywords/usp7-inhibitors","display_name":"USP7 inhibitors","score":0.7559999823570251},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.46399998664855957},{"id":"https://openalex.org/keywords/flt3-inhibitors","display_name":"FLT3 inhibitors","score":0.628000020980835},{"id":"https://openalex.org/keywords/midostaurin","display_name":"midostaurin","score":0.7910000085830688},{"id":"https://openalex.org/keywords/ba-f3-cells","display_name":"Ba/F3 cells","score":0.8410000205039978},{"id":"https://openalex.org/keywords/leukemia-cell-lines","display_name":"leukemia cell lines","score":0.6269999742507935},{"id":"https://openalex.org/keywords/selective-cytotoxicity","display_name":"selective cytotoxicity","score":0.5170000195503235}],"concepts":[{"id":"https://openalex.org/C2776481607","wikidata":"https://www.wikidata.org/wiki/Q6842945","display_name":"Midostaurin","level":3,"score":0.8957735300064087},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6679508686065674},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5891308188438416},{"id":"https://openalex.org/C2910954276","wikidata":"https://www.wikidata.org/wiki/Q14912399","display_name":"Fms-Like Tyrosine Kinase 3","level":4,"score":0.5374999046325684},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.46586039662361145},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.45999324321746826},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.4492727816104889},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.38658952713012695},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35766416788101196},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33136987686157227},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.22208547592163086},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.1686890423297882}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v128.22.524.524","doi":"https://doi.org/10.1182/blood.v128.22.524.524","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v128.22.524.524","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8100000023841858,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4409821658","https://openalex.org/W2762414284","https://openalex.org/W3045113956","https://openalex.org/W3041031914","https://openalex.org/W3004175467","https://openalex.org/W4285393247","https://openalex.org/W3213453638","https://openalex.org/W6990061303","https://openalex.org/W3096826855","https://openalex.org/W3092634901"],"abstract_inverted_index":{"Abstract":[0],"Acute":[1],"myeloid":[2],"leukemia":[3,12,253],"(AML)":[4],"is":[5,21,297,310,400,555],"the":[6,16,39,52,126,142,175,198,234,243,267,277,295,327,333,347,378,421,438,475,479,556],"most":[7,43,328],"common":[8,44],"type":[9],"of":[10,31,58,94,130,170,197,206,251,276,279,289,306,332,355,375,384,437,441,462,502,535,559,561,648,662],"acute":[11],"in":[13,48,56,91,107,137,141,149,201,367,402,541],"adults.":[14],"Overall,":[15,496],"survival":[17,117],"with":[18,26,66,120,139,152,160,456,549],"current":[19],"chemotherapy":[20],"only":[22,263],"20-40%,":[23],"declining":[24],"steadily":[25],"advancing":[27],"age.":[28],"Approximately":[29],"30%":[30],"AML":[32,59,96,155,202,466,470,563],"patients":[33,60,97,138,151,159],"have":[34,81],"mutations":[35,140,547],"that":[36,128,174,283,294,349,431,450],"constitutively":[37],"activate":[38],"FLT3":[40,45,70,131,143,167,191,381,445,457,480,486,504,542,577],"gene.":[41,144],"The":[42,237],"mutation":[46],"results":[47],"tandem":[49,62],"duplications":[50],"within":[51],"juxtamembrane":[53],"domain,":[54],"observed":[55,401,449],"20-25%":[57],"(internal":[61],"duplication,":[63],"ITD),":[64],"associated":[65,548],"markedly":[67],"decreased":[68],"survival.":[69],"kinase":[71,458,487,525,551],"domain":[72],"inhibitors,":[73,459],"including":[74],"SU11248,":[75],"SU5416,":[76],"CEP-701":[77],"and":[78,87,156,293,358,364,380,388,392,398,417,425,468,492,532,537,571],"PKC412":[79],"(midostaurin),":[80],"been":[82],"shown":[83,114],"to":[84,115,165,194,214,242,264,343,477,509],"induce":[85],"partial,":[86],"usually":[88],"brief,":[89],"remissions":[90],"clinical":[92],"trials":[93],"relapsed":[95],"when":[98,118,246],"administered":[99],"as":[100,233,299,312,326,346,505],"single":[101],"agents.":[102],"In":[103,435],"a":[104,185,229,249,258,353,393,428,568,573],"large":[105],"trial":[106],"newly":[108,153],"diagnosed":[109,154],"patients,":[110],"however,":[111],"midostaurin":[112],"was":[113],"increase":[116],"combined":[119],"standard":[121],"chemotherapy.[1]":[122],"This":[123,513],"study":[124],"supports":[125],"notion":[127],"inhibition":[129,443],"may":[132],"be":[133,169],"important,":[134],"at":[135],"least":[136],"Since":[145],"drug":[146],"resistance":[147],"develops":[148],"some":[150,550],"virtually":[157],"all":[158],"advanced":[161],"disease,":[162],"additional":[163],"strategies":[164],"target":[166,511],"would":[168],"value.":[171],"We":[172,340],"discovered":[173],"deubiquitinating":[176],"enzyme":[177,570],"(DUB)":[178],"ubiquitin":[179,187],"specific":[180],"protease":[181],"10":[182],"(USP10)":[183],"removes":[184],"degradative":[186],"tag":[188],"from":[189],"mutant":[190,446,463,482,503,564],"thereby":[192],"contributing":[193],"high":[195],"levels":[196,305],"oncogenic":[199],"protein":[200,304,543,566],"(Fig":[203,270,291,405],"1a).":[204],"Screening":[205],"our":[207,497],"preclinical":[208],"DUB":[209,331,348,569],"inhibitor":[210,453],"library":[211],"for":[212,420,444,576],"ability":[213,476],"selectively":[215],"kill":[216],"growth":[217,260,461],"factor-independent":[218],"FLT3-ITD-positive":[219],"Ba/F3":[220,225,244],"cells":[221,226,368,467,471],"over":[222],"IL-3-dependent":[223],"parental":[224],"identified":[227,427],"HBX19818,":[228],"reported":[230],"USP7":[231,315],"inhibitor,":[232],"top":[235],"hit.":[236],"effects":[238,383,419],"are":[239],"not":[240,302,370,390,494],"unique":[241],"system:":[245],"profiled":[247],"against":[248],"panel":[250],"7":[252],"cell":[254],"lines,":[255],"HBX19818":[256,280,300,309,362,385,422],"conferred":[257],"substantial":[259],"suppressive":[261],"effect":[262,296],"those":[265],"expressing":[266],"FLT3-ITD":[268,290,351,399,415],"oncoprotein":[269],"1b).":[271],"As":[272],"an":[273,313,506,562,645,659],"initial":[274],"assessment":[275],"mechanism":[278],"we":[281,322,426,448],"confirmed":[282],"it":[284],"does":[285,301],"promote":[286],"ubiquitin-mediated":[287],"degradation":[288,382,416,501],"1c)":[292],"selective":[298],"impact":[303],"wt":[307],"FLT3.":[308,512],"published":[311],"irreversible":[314],"inhibitor,[2]":[316],"however":[317],"DUBome":[318],"selectivity":[319],"profiling":[320],"data":[321,389,493,498],"generated":[323],"identifies":[324],"USP10":[325,345,366,376,397,413,442,452],"potently":[329],"inhibited":[330],"compound":[334],"(USP10":[335],"IC50":[336],"=":[337],"14":[338],"\u00b5M).":[339],"went":[341],"on":[342,517,644,658],"validate":[344],"stabilizes":[350],"using":[352],"combination":[354],"small":[356,372],"molecule":[357],"genetic":[359],"experiments.":[360],"Notably,":[361],"binds":[363],"inhibits":[365],"(data":[369],"shown),":[371,391],"hairpin":[373],"knockdown":[374],"phenocopies":[377,432],"antiproliferative":[379],"(Figure":[386],"1d":[387],"direct":[394],"interaction":[395],"between":[396],"co-immunoprecipitation":[403],"experiments":[404],"1e).":[406],"Additionally,":[407],"SAR":[408],"studies":[409],"reveal":[410],"correlation":[411],"among":[412,484],"IC50,":[414],"anti-proliferative":[418],"chemical":[423],"series,":[424],"second":[429],"chemotype":[430],"its":[433],"effects.":[434],"support":[436,500],"translational":[439],"potential":[440],"AML,":[447],"both":[451,530],"series":[454],"synergize":[455],"suppress":[460],"FLT3-expressing":[464],"primary":[465],"primagraft":[469],"and,":[472],"importantly,":[473],"display":[474],"overcome":[478],"inhibitor-resistant":[481,488],"FLT3-ITD-F691L":[483],"other":[485],"mutants":[489],"(Fig.":[490],"1f":[491],"shown).":[495],"strongly":[499],"alternative":[507],"approach":[508],"therapeutically":[510],"approach,":[514],"which":[515],"focuses":[516],"targeting":[518],"USP10,":[519],"could":[520],"prove":[521],"more":[522],"efficacious":[523],"than":[524],"inhibitors":[526],"by":[527,567],"simultaneously":[528],"blocking":[529,538],"enzymatic":[531],"scaffolding":[533],"functions":[534],"FLT3,":[536],"compensatory":[539],"increases":[540],"or":[544,650,664],"resistant":[545],"point":[546],"inhibitors.":[552],"Importantly,":[553],"this":[554],"first":[557],"demonstration":[558],"stabilization":[560],"driver":[565],"introduces":[572],"novel":[574],"therapy":[575],"mutant-positive":[578],"AML.":[579],"References:":[580],"1.":[581,597,599],"Stone,":[582],"R.M.,":[583],"ASH,":[584],"2015.":[585],"2.":[586],"Reverdy,":[587],"C.,":[588],"et":[589],"al.,":[590],"Chem":[591],"Biol,":[592],"2012.":[593],"19,":[594],"467-77.":[595],"Figure":[596,598],"Disclosures":[600],"Weisberg:":[601],"novartis:":[602],"Research":[603,607,690,694],"Funding.":[604,608,695],"Weinstock:Novartis:":[605],"Consultancy,":[606,642,656,678,682,686,693],"Stone:Celator:":[609],"Consultancy;":[610,612,615,617,620,622,624,626,629,632,635,638,640,654,669,671],"Pfizer:":[611],"Xenetic":[613,627],"Biosciences:":[614,628],"Novartis:":[616,692],"Seattle":[618,667],"Genetics:":[619,668],"Roche:":[621],"Amgen:":[623],"ONO:":[625],"Sunesis":[630,636],"Pharmaceuticals:":[631,637],"Juno":[633],"Therapeutics:":[634],"Karyopharm:":[639],"Celgene:":[641],"Membership":[643,657],"entity's":[646,660],"Board":[647,661],"Directors":[649,663],"advisory":[651,665],"committees;":[652,666],"Merck:":[653],"Abbvie:":[655],"Agios:":[670],"Jansen:":[672],"Consultancy.":[673],"Gray:Gatekeeper:":[674],"Equity":[675,679,683,687],"Ownership;":[676,680,684],"Petra:":[677],"C4:":[681],"Syros:":[685],"Ownership.":[688],"Griffin:Janssen:":[689],"Funding;":[691]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2019-10-18T00:00:00"}